{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T04:06:08Z","timestamp":1785038768489,"version":"3.55.0"},"reference-count":41,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,5,22]]},"abstract":"<jats:title>Key Points<\/jats:title><jats:p>This study shows the effective anticancer activity of a T-cell receptor mimic antibody targeting WT1 in resistant human Ph+ ALL. In combination with tyrosine kinase inhibitors, ESKM can result in cure of Ph+ ALL in murine models.<\/jats:p>","DOI":"10.1182\/blood-2014-01-549022","type":"journal-article","created":{"date-parts":[[2014,4,11]],"date-time":"2014-04-11T06:28:28Z","timestamp":1397197708000},"page":"3296-3304","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":46,"title":["A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias"],"prefix":"10.1182","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2799-4765","authenticated-orcid":false,"given":"Leonid","family":"Dubrovsky","sequence":"first","affiliation":[{"name":"Molecular Pharmacology and Chemistry Program, Sloan-Kettering Institute, New York, NY;"},{"name":"Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry","family":"Pankov","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology and Chemistry Program, Sloan-Kettering Institute, New York, NY;"},{"name":"Immunology Program, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliott Joseph","family":"Brea","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology and Chemistry Program, Sloan-Kettering Institute, New York, NY;"},{"name":"Weill Cornell Medical College, New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Dao","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology and Chemistry Program, Sloan-Kettering Institute, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Scott","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology and Chemistry Program, Sloan-Kettering Institute, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su","family":"Yan","sequence":"additional","affiliation":[{"name":"Eureka Therapeutics, Emeryville, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J","family":"O\u2019Reilly","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology and Chemistry Program, Sloan-Kettering Institute, New York, NY;"},{"name":"Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY;"},{"name":"Immunology Program, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Liu","sequence":"additional","affiliation":[{"name":"Eureka Therapeutics, Emeryville, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Scheinberg","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology and Chemistry Program, Sloan-Kettering Institute, New York, NY;"},{"name":"Weill Cornell Medical College, New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"4","key":"2019111819194670000_B1","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/0888-7543(92)90313-H","article-title":"The genomic organization and expression of the WT1 gene.","volume":"12","author":"Gessler","year":"1992","journal-title":"Genomics"},{"issue":"21","key":"2019111819194670000_B2","doi-asserted-by":"crossref","first-page":"9618","DOI":"10.1073\/pnas.88.21.9618","article-title":"Alternative splicing and genomic structure of the Wilms tumor gene WT1.","volume":"88","author":"Haber","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"2019111819194670000_B3","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.pep.2005.10.029","article-title":"Expression, purification, and characterization of the 4 zinc finger region of human tumor suppressor WT1.","volume":"46","author":"Nurmemmedov","year":"2006","journal-title":"Protein Expr Purif"},{"issue":"6280","key":"2019111819194670000_B4","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/346194a0","article-title":"The candidate Wilms\u2019 tumour gene is involved in genitourinary development.","volume":"346","author":"Pritchard-Jones","year":"1990","journal-title":"Nature"},{"issue":"13","key":"2019111819194670000_B5","doi-asserted-by":"crossref","first-page":"9172","DOI":"10.1016\/S0021-9258(18)98329-8","article-title":"The Wilms\u2019 tumor gene product WT1 activates or suppresses transcription through separate functional domains.","volume":"268","author":"Wang","year":"1993","journal-title":"J Biol Chem"},{"issue":"1","key":"2019111819194670000_B6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/ajh.21915","article-title":"Characterization of chronic myeloid leukemia stem cells.","volume":"86","author":"Gerber","year":"2011","journal-title":"Am J Hematol"},{"issue":"2","key":"2019111819194670000_B7","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/088800199277434","article-title":"Expression of Wilms tumor gene (WT1) in children with acute leukemia.","volume":"16","author":"Im","year":"1999","journal-title":"Pediatr Hematol Oncol"},{"issue":"6","key":"2019111819194670000_B8","first-page":"1060","article-title":"Presence of Wilms\u2019 tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias.","volume":"9","author":"Menssen","year":"1995","journal-title":"Leukemia"},{"issue":"2","key":"2019111819194670000_B9","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000040973","article-title":"wt1 gene expression in childhood leukemias.","volume":"102","author":"Niegemann","year":"1999","journal-title":"Acta Haematol"},{"issue":"3","key":"2019111819194670000_B10","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/sj.leu.2401341","article-title":"The Wilms\u2019 tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes.","volume":"13","author":"Tamaki","year":"1999","journal-title":"Leukemia"},{"issue":"2","key":"2019111819194670000_B11","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1349-7006.1999.tb00733.x","article-title":"Expression of the Wilms\u2019 tumor gene WT1 in solid tumors and its involvement in tumor cell growth.","volume":"90","author":"Oji","year":"1999","journal-title":"Jpn J Cancer Res"},{"issue":"2","key":"2019111819194670000_B12","first-page":"344","article-title":"Wilms\u2019 tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma.","volume":"146","author":"Amin","year":"1995","journal-title":"Am J Pathol"},{"issue":"1","key":"2019111819194670000_B13","first-page":"17","article-title":"The value of PAX8 and WT1 molecules in ovarian cancer diagnosis.","volume":"54","author":"Liliac","year":"2013","journal-title":"Rom J Morphol Embryol"},{"issue":"4","key":"2019111819194670000_B14","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/PAI.0b013e31815c2e02","article-title":"Cytoplasmic overexpression of WT-1 in gastrointestinal stromal tumor and other soft tissue tumors.","volume":"16","author":"Bing","year":"2008","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"1","key":"2019111819194670000_B15","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3109\/00313020903434413","article-title":"WT-1 expression in gastrointestinal stromal tumours.","volume":"42","author":"Kang","year":"2010","journal-title":"Pathology"},{"issue":"1","key":"2019111819194670000_B16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1365-2990.2008.00957.x","article-title":"Diagnostic value of WT1 in neuroepithelial tumours.","volume":"35","author":"Schittenhelm","year":"2009","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"26","key":"2019111819194670000_B17","doi-asserted-by":"crossref","first-page":"6541","DOI":"10.1182\/blood-2009-02-202598","article-title":"A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS.","volume":"113","author":"Keilholz","year":"2009","journal-title":"Blood"},{"issue":"8","key":"2019111819194670000_B18","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1182\/blood-2011-11-394619","article-title":"Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(+) leukemias.","volume":"120","author":"Doubrovina","year":"2012","journal-title":"Blood"},{"issue":"Suppl 2","key":"2019111819194670000_B19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3109\/14767058.2011.606619","article-title":"Expression of WT1 during normal human kidney development.","volume":"24","author":"Fanni","year":"2011","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"17","key":"2019111819194670000_B20","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","article-title":"The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research.","volume":"15","author":"Cheever","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2019111819194670000_B21","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1182\/blood-2009-10-250993","article-title":"Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia.","volume":"116","author":"Maslak","year":"2010","journal-title":"Blood"},{"issue":"11","key":"2019111819194670000_B22","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1517\/14712598.2013.833602","article-title":"Therapeutic antibodies to intracellular targets in cancer therapy.","volume":"13","author":"Veomett","year":"2013","journal-title":"Expert Opin Biol Ther"},{"issue":"176","key":"2019111819194670000_B23","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005661","article-title":"Targeting the intracellular WT1 oncogene product with a therapeutic human antibody.","volume":"5","author":"Dao","year":"2013","journal-title":"Sci Transl Med"},{"issue":"16","key":"2019111819194670000_B24","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1182\/blood-2010-07-299248","article-title":"An anti-PR1\/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells.","volume":"117","author":"Sergeeva","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2019111819194670000_B25","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","article-title":"Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-Study IV.","volume":"32","author":"Hehlmann","year":"2014","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111819194670000_B26","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/ajh.23180","article-title":"Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia.","volume":"87","author":"Jabbour","year":"2012","journal-title":"Am J Hematol"},{"issue":"4","key":"2019111819194670000_B27","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.clml.2012.04.002","article-title":"Adherence to BCR-ABL inhibitors: issues for CML therapy.","volume":"12","author":"Jabbour","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"2019111819194670000_B28","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.3109\/10428194.2012.695779","article-title":"Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia.","volume":"53","author":"Steegmann","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"19","key":"2019111819194670000_B29","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111819194670000_B30","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/cncr.27901","article-title":"Treatment of adults with acute lymphoblastic leukemia: do the specifics of the regimen matter?: Results from a prospective randomized trial.","volume":"119","author":"Lamanna","year":"2013","journal-title":"Cancer"},{"issue":"9","key":"2019111819194670000_B31","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1073\/pnas.0409770102","article-title":"Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance.","volume":"102","author":"Burgess","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"2019111819194670000_B32","doi-asserted-by":"crossref","first-page":"6477","DOI":"10.4049\/jimmunol.174.10.6477","article-title":"Human lymphoid and myeloid cell development in NOD\/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells.","volume":"174","author":"Shultz","year":"2005","journal-title":"J Immunol"},{"issue":"1","key":"2019111819194670000_B33","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3109\/10428194.2011.601698","article-title":"Enhancement of the anti-tumor activity of therapeutic monoclonal antibodies by CXCR4 antagonists.","volume":"53","author":"Hu","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2019111819194670000_B34","first-page":"447","article-title":"Establishment of a Ph1-positive human cell line (BV173).","volume":"70","author":"Pegoraro","year":"1983","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"2019111819194670000_B35","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.leukres.2007.11.008","article-title":"Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines.","volume":"32","author":"Deguchi","year":"2008","journal-title":"Leuk Res"},{"issue":"1","key":"2019111819194670000_B36","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/BF00688950","article-title":"The mouse blood-brain barrier and blood-nerve barrier for IgG: a tracer study by use of the avidin-biotin system.","volume":"68","author":"Seitz","year":"1985","journal-title":"Acta Neuropathol"},{"issue":"4","key":"2019111819194670000_B37","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00262-012-1373-7","article-title":"Imatinib mesylate and nilotinib affect MHC-class I presentation by modulating the proteasomal processing of antigenic peptides.","volume":"62","author":"Held","year":"2013","journal-title":"Cancer Immunol Immunother"},{"issue":"12","key":"2019111819194670000_B38","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1038\/sj.leu.2404924","article-title":"Deregulation of the Wilms\u2019 tumour gene 1 protein (WT1) by BCR\/ABL1 mediates resistance to imatinib in human leukaemia cells.","volume":"21","author":"Svensson","year":"2007","journal-title":"Leukemia"},{"key":"2019111819194670000_B39","article-title":"Targeting the intracellular WT1 oncoprotein with multiple therapeutic antibody modalities.","author":"Veomett"},{"issue":"6","key":"2019111819194670000_B40","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1182\/blood-2005-03-1036","article-title":"High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy.","volume":"106","author":"Willis","year":"2005","journal-title":"Blood"},{"issue":"12","key":"2019111819194670000_B41","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1182\/blood-2007-03-080838","article-title":"Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.","volume":"110","author":"Cortes","year":"2007","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/123\/21\/3296\/1377629\/3296.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/123\/21\/3296\/1377629\/3296.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T11:35:01Z","timestamp":1648812901000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/123\/21\/3296\/32784\/A-TCRmimic-antibody-to-WT1-bypasses-tyrosine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,22]]},"references-count":41,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2014,5,22]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2014-01-549022","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,22]]}}}